title: Ustekinumab associated thrombotic thrombocytopenic purpura.
abstract: Thrombotic thrombocytopenic purpura (TTP) is a rare disorder. Plasma exchange therapy has been shown to significantly reduce mortality in patients with TTP. Here, we report a case of TTP associated with ustekinumab therapy after a period of 2-3 years. Ustekinumab, a monoclonal antibody that inhibits interleukin 12 and interleukin 23, is one of the newer treatments for psoriasis. Although our patient experienced a prolonged course of TTP requiring 1 month of daily plasma exchange therapy, he recovered and remains in remission after 6 months.
authors.affiliation: The University of Western Ontario, Department of Medicine, Nephrology Division, and London Health Sciences Centre, London, Canada. shuang45@uwo.ca
authors.forename: Shih-Han S
authors.initials: SH
authors.lastname: Huang
authors.forename: A
authors.initials: A
authors.lastname: Xenocostas
authors.forename: L M
authors.initials: LM
authors.lastname: Moist
authors.forename: M
authors.initials: M
authors.lastname: Crowther
authors.forename: J C
authors.initials: JC
authors.lastname: Moore
authors.forename: W F
authors.initials: WF
authors.lastname: Clark
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D008297:Male; D010956:Plasmapheresis / Q000379:methods; D011697:Purpura, Thrombotic Thrombocytopenic / Q000139:chemically induced*; D016896:Treatment Outcome; D000069549:Ustekinumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069549:Ustekinumab